Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Creative Medical Technology (OTCMKTS:CELZ – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares Genocea Biosciences and Creative Medical Technology's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Genocea Biosciences and Creative Medical Technology's revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

9.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 10.7% of Creative Medical Technology shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.8% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Genocea Biosciences and Creative Medical Technology, as provided by MarketBeat.com.

Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 37,874.68%. Creative Medical Technology has a consensus price target of $10.00, suggesting a potential upside of 2,453.63%. Given Genocea Biosciences' higher probable upside, equities research analysts clearly believe Genocea Biosciences is more favorable than Creative Medical Technology.

Summary

Creative Medical Technology beats Genocea Biosciences on 8 of the 11 factors compared between the two stocks.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

About Creative Medical Technology

(Get Rating)

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.